Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motion Sickness Medications and Vestibular Time Constant
NCT03270839Phase 4Completed
- Sponsor
- Israel Defense Forces Medical Corps
- Start
- Jun 2017
- Primary completion
- Sep 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of scopolamine and meclizine in motion sickness (8 arms), sponsored by Israel Defense Forces Medical Corps. Primary endpoints: Vestibular Time Constant Change/differential at 2 hours, Step Velocity Test Gain Change/differential at 2 hours and 6 more. Started Jun 2017; status: completed.
02
Drugs
scopolaminemeclizine
03
Conditions
motion sickness
Beyond the preview
Go deeper on NCT03270839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03270839.